The Lancet journals: Papers at ERS Congress 2019

September 30, 2019

The following papers will be presented at the ERS Congress 2019, organised by the European Respiratory Society, in Madrid and published simultaneously in either The Lancet or The Lancet Respiratory Medicine journals. All papers are under embargo until the stated time. Contact details for corresponding authors are provided in the Articles and linked Comments. Funding information is listed on the first page of each Article.

Embargo: 23.30hrs [UK time] / 6.30pm [New York time] Friday 27th September / 00.30hrs [Madrid time] on Saturday 28th September 2019

The Lancet Respiratory Medicine: The future of cystic fibrosis care - a global perspective Authors of a newCommission on cysticfibrosis call for renewed efforts to turn acutely fatal disease into a manageable condition - asapatient perspective, also published inThe Lancet Respiratory Medicine, highlightstheneed for solutions to a "funding impasse" that prevents newcysticfibrosis drugs from reaching patients

The past six decades have seen remarkable improvements in health outcomes for people with cystic fibrosis, which was once a fatal disease of infants and young children. However, although life expectancy for people with cystic fibrosis has increased substantially, the disease continues to limit survival and quality of life, and results in a large burden of care for people with cystic fibrosis and their families.

New CFTR modulator drugs are showing promise in up to 90% of patients, including in patients with CFTR mutations for which earlier modulators were ineffective, but current drug prices make them unaffordable for many LMICs, and even in some developed countries, governments have not yet funded these therapies.

Professor Bell and Toronto-based Paediatrician and Clinician Scientist, Professor Felix Ratjen, have led a total team of 38 world-leading, inter-disciplinary contributors over the past 18 months, to author The Lancet Respiratory Medicine Commission on the Future of Care of Cystic Fibrosis: a global perspective. The team will launch the Commission at the European Respiratory Society Congress on Sunday 29th September in Madrid, Spain.

London based Cystic Fibrosis Patient, Sally Brennan, shares her story and reflections on the findings of the Commission in a comment published The Lancet Respiratory Medicine - calling in particular for a solution to the National Health Service funding impasse that currently prevents the new generation of drugs that target the CFTR from being made available to all those who would benefit. She states: "I sincerely hope that these new drugs, which have the potential to radically change how cystic fibrosis progresses, mean that my generation is one of the last to endure the trauma and uncertainty of lung transplantation."

Embargo: 23.01hrs [UK time] / 6.01pm [New York time] on Saturday 28th September / 00.01hrs [Madrid time] on Sunday 29th September 2019

The Lancet Respiratory Medicine: Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial Embargo: 23.01hrs [UK time] / 6.01pm [New York time] on Saturday 28th September / 00.01hrs [Madrid time] on Sunday 29th September 2019

The Lancet Respiratory Medicine: Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies

Embargo: 23.01hrs [UK time] / 6.01pm [New York time] on Sunday 29th September / 00.01hrs [Madrid time] on Monday 30th September 2019

The Lancet Respiratory Medicine: Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Embargo: 23.01hrs [UK time] / 6.01pm [New York time] on Sunday 29th September / 00.01hrs [Madrid time] on Monday 30th September 2019

The Lancet Respiratory Medicine: Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study

Embargo:23.01hrs [UK time] / 6.01pm [New York time] on Monday 30th September / 00.01hrs [Madrid time] on Tuesday 1st October 2019

The Lancet: Three-in-one inhaler therapy can improve lung function and reduce asthma attacks Patients with severe asthma which is not controlled with standard treatment - leaving them at risk of severe asthma attacks - could benefit from using a single inhaler combining three, instead of two therapies, according to two phase 3 randomised controlled trials with over 2,500 patients across 17 countries, published in The Lancet and simultaneously presented at the European Respiratory Society (ERS) Conference 2019.

Full press release issued earlier today.
-end-


The Lancet

Related Cystic Fibrosis Articles from Brightsurf:

Treating cystic fibrosis with mRNA therapy or CRISPR
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation.

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

A newly discovered disease may lead to better treatment of cystic fibrosis
Cystic fibrosis is the most frequent severe inherited disorder worldwide.

New treatment kills off infection that can be deadly to cystic fibrosis patients
The findings, which are published in the journal Scientific Reports, show that scientists from Aston University, Mycobacterial Research Group, combined doses of three antibiotics -- amoxicillin and imipenem-relebactam and found it was 100% effective in killing off the infection which is usually extremely difficult to treat in patients with cystic fibrosis.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Rare mutations drive cystic fibrosis in Caribbean
Cystic Fibrosis (CF) in the Caribbean is dominated by unusual gene mutations not often observed in previously studied CF populations, according to comprehensive genome sequencing led by physician-scientists at UC San Francisco and Centro de Neumología Pediátrica in San Juan.

Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to those of people with cystic fibrosis.

In cystic fibrosis, lungs feed deadly bacteria
A steady supply of its favorite food helps a deadly bacterium thrive in the lungs of people with cystic fibrosis, according to a new study by Columbia researchers.

Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.

Hypertonic saline may help babies with cystic fibrosis breathe better
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read More: Cystic Fibrosis News and Cystic Fibrosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.